FAF1-Loaded Exosome Cell Lines for Inducible High-Yield Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing technologies face challenges in developing cell lines that can mass-produce exosomes loaded with proteins inducing apoptosis, such as FAF1, without affecting cell survival and proliferation, and there is a need for a stable expression system to overcome the adverse effects of these proteins on cell viability.
Innovation Solution
A cell line is developed by transducing a vector containing a gene encoding FAF1 protein and a promoter into various cell types, followed by culturing and screening to stabilize exosome expression, allowing for high-yield production of FAF1-loaded exosomes using an inducible promoter system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a cell line is used to produce FAF1 protein which induces apoptosis, then the therapeutic effect is improved, but cell survival and proliferation are adversely affected
Solution Approach 1:
The patent segments the FAF1 protein production process from the cell proliferation process by using an inducible promoter system. The FAF1 gene is integrated into the cell genome but only expressed when the inducer (doxycycline) is present, allowing cell culture to proceed normally during proliferation phases and only producing FAF1 when needed for therapeutic collection.
Solution Approach 2:
The patent performs preliminary action by pre-integrating the FAF1 gene into the cell genome using a vector system before large-scale culture. The cell line is prepared in advance with the capability to produce FAF1, but the actual protein production is triggered only when needed through inducer addition, allowing cells to establish and proliferate first.
2Quantity of substance
If the expression of FAF1 protein is increased to improve therapeutic yield, then the amount of apoptosis-induced harmful effects increases
Solution Approach 1:
The patent implements periodic action by using cyclic induction with doxycycline. The inducer is added to the culture medium at specific time points during cell cultivation to trigger FAF1 expression, allowing the system to oscillate between high proliferation (no inducer) and high production (inducer present) states, maximizing both cell growth and therapeutic yield.
Solution Approach 2:
The patent changes the expression parameter of FAF1 protein by using an inducible promoter system. The promoter activity can be switched between active and inactive states by adding or removing the inducer (doxycycline), allowing precise control over the quantity of FAF1 protein produced and thereby controlling the level of apoptosis-induced harmful effects.
3Productivity
If an inducible promoter system is used to control FAF1 expression, then cell productivity is improved, but the system complexity increases
Solution Approach 1:
The patent uses an intermediary substance (doxycycline) to control the gene expression system. The tetracycline-responsive promoter (TRE3G) acts as an intermediary mechanism between the inducer and the FAF1 gene, translating the presence or absence of doxycycline into controlled protein expression. This intermediary system provides simple external control (adding/removing drug) for complex internal regulation.
Data Source
Figure 1
Figure 2~3
Figure 4
AI summary
According to an aspect of the technology disclosed in the present application, the present invention relates to a cell line in which exosomes loaded with FAF 1 protein are stably expressed, and relates to: a cell line, which can produce, in a high yield, exosomes loaded with FAF 1 protein and selectively modulate the expression of FAF1 protein; a method for preparing the cell line; and a method for producing exosomes loaded with FAF 1 protein.